The study looks at how safe and effective a new drug, **TCD601**, is for people who just had a **kidney transplant**. TCD601 is used with another medicine called **Belatacept**. The study compares this combination to the usual medicines given after a transplant to stop the body from rejecting the new kidney. Belatacept is part of a group of medicines called **immunosuppressants**, which help the body accept the new organ by weakening the immune system. The goal is to see if TCD601 and Belatacept work as well or better than the regular treatment.

• The study is for people aged 18 to 70 who are receiving their first kidney transplant.
• Participants must not have had a kidney transplant before.
• They must also not receive a kidney from a donor who has died from heart problems.

Being part of this study might involve new treatments and visits to the doctor for checkups. It is important to understand the study and agree to participate by signing a consent form. Talk to your doctor to see if this study is right for you.